Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data
Interim results from phase 2 proof-of-concept study, using LUNAR-CF for treatment of patients with Cystic Fibrosis, expected 1st half of 2025. The global Cystic Fibrosis market size is projected to reach $62.57 billion by 2032. Interim results from phase 2 proof-of-concept study, using LUNAR-OTC for treatment of patients with OTC Deficiency, expected 1st half of 2025.
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joseph Payne - President and CEO Andrew Sassine - CFO Pad Chivukula - CSO & COO Conference Call Participants Lili Nsongo - Leerink Whitney Ijem - Canaccord Genuity Evan Wang - Guggenheim Securities Myles Minter - William Blair Samantha Schaeffer - Cantor Fitzgerald Yale Jen - Laidlaw & Company Yigal Nochomovitz - Citi Operator Good day, everyone, and welcome to today's Arcturus Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.61 per share a year ago.
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect
On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.
Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock?
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
Here's Why Investors Should Invest in Arcturus Stock Now
Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move.
Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 216.4% in Arcturus Therapeutics (ARCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
Arcturus is close to launching the Kostaive COVID-19 vaccine in Japan, with ongoing work on variant protection and influenza vaccine. The company has been able to consistently derive research revenues, maintaining liquidity and avoiding debt, with potential for significant revenue from vaccine orders. Valuation suggests Arcturus may be undervalued compared to peers, with a revised model showing potential for significant revenue growth by 2026.
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q2 2024 Earnings Call Transcript August 5, 2024 4:30 PM ET Company Participants Neda Safarzadeh - VP, Head of IR, Public Relations and Marketing Joe Payne - President and CEO Andy Sassine - CFO Conference Call Participants Joohwan Kim - Canaccord Genuity Yasmeen Rahimi - Piper Sandler Evan Wang - Guggenheim Securities Myles Minter - William Blair Yanan Zhu - Wells Fargo Yigal Nochomovitz - Citigroup Samantha Schaeffer - Cantor Fitzgerald Ed Arce - H.C. Wainwright Yale Jen - Laidlaw & Company Operator Greetings and welcome to Arcturus Therapeutics' Second Quarter 2024 Earnings Call.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $1.85. This compares to loss of $1.98 per share a year ago.
